Advertisement · 728 × 90
#
Hashtag
#hypercholesterolemia
Advertisement · 728 × 90
Medications are expensive So, being unemployed, I have to pay my own health insurance. This is currently around $500/month. This insurance uses high copays on medication in order to “encourage the use” of cheaper medications. I have four medications which are expensive and get a $100/month copay, so I’m still paying $400/month on those meds. Two of those meds have copay assistance programs, which present their own set of problems, and insurance companies _hate_ that they exist, because they’re a retroactive incentive to make it easier for people to swallow the high copays on the meds while insurance still has to pay the bulk of the price, and the pharmaceutical companies bake the copay assistance program discount into the retail price of the medicine anyway so it’s not like they’re hurt by it _at all_. But if I had to pay out-of-pocket for these meds, I’d be paying more for them than for my house. Here’s the four medications that I’m on which are this expensive, and why they really shouldn’t be: ### Xarelto (rivaroxaban) * Purpose: Blood thinner * Copay: $100/month * Retail price: $600 After my first DVT (the one which turned into an embolism and almost killed me) I was on warfarin, a very cheap, generic blood thinner, but it requires constant monitoring and since it was my first DVT, treatment called for only a six-month course with monitoring. After my second DVT indicated that this is a chronic condition, I’ve been on Xarelto, a blood thinner that is self-regulating and doesn’t put me in as much danger of spontaneous hemorrhages. It also means not having to do weekly bloodwork with my doctor. Xarelto’s patents have all expired as of 2025 and there are several generics that have been approved by the FDA, but they all cost just as much as the original and aren’t available in the dose I take anyway. ### Repatha (evolocumab) * Purpose: anti-cholesterol * Copay: $100/month * Retail price: $240 I have familial hypercholesterolemia, which is to say that at a genetic level my liver produces way too much cholesterol. I inherited this from my dad. Regardless of diet or exercise my cholesterol levels are always super high. I also cannot tolerate statins, which cause me massive, _excruciating_ full-body pain, along with muscle failure. So, Repatha is the only cholesterol-lowering treatment that I can tolerate, and it works great! It’s a biweekly injection of monoclonal antibodies which break down the cholesterol itself. It’s a really cool immune system hack and it’s been super effective. But it will be protected by patents until 2033 at the very earliest. ### Depo-Estradiol (estradiol cypionate) * Purpose: hormone replacement * Copay: $100/month * Retail price: $240 I’ve written extensively about my ongoing HRT battles, and Depo-Estradiol is what I’ve been taking for the last few weeks. It’s been pretty effective so far. There are two common forms of injectable estradiol: valerate and cypionate. The main difference between them is the carrier oil that’s used. Valerate uses castor oil, which is cross-reactive for folks with peanut allergies, and also has a tendency to generate allergies of its own. I am sensitive to peanuts and have a bunch of other allergies, so out of an abundance of caution, I take cypionate instead. Valerate’s retail price is $52, and my copay on it would be $5. Cypionate costs 50x as much. All for a different carrier oil. Cypionate’s patents don’t expire until 2034. ### Tonmya (cyclobenzaprine, sublingual) * Purpose: sleep aid, chronic pain relief * Copay: $100/month * Retail price: $1800 Cyclobenzaprine is a muscle relaxant that also helps with other aspects of fibromyalgia. It’s a well-known, super-cheap medication. Its ordinary oral formulation has a retail price of around $13. Unfortunately, as an oral formulation it lingers in the system and has other long-term effects, as it’s processed by the liver. For me it’s a suitable rescue medication when I’m having especially bad pain flareups, but it makes me unable to do anything the next day due to extreme fatigue. Recently, Tonmya came to market, as a sublingual, rapid-release formulation of cyclobenzaprine. As far as I can tell it is the exact same medication as before, just in a different carrier that allows it to be taken sublingually, so that it absorbs right into my blood stream and bypasses the liver. It’s also a much smaller dose, as 2.5mg knocks me out in 10-15 minutes and gives me 7-8 hours of pretty decent sleep (albeit with some _really_ intense dreams). My generic cyclobenzaprine has a dose of 10mg (4x as much), takes hours to kick in, and stays with me all day long. Just by changing up the carrier, though, they were able to jack up the price by around 140x, for a drug that only has niche usage (namely fibromyalgia) from a population that just plan can’t afford it (because folks with fibromyalgia tend not to be super-employed). Its patents don’t expire until 2034. ### Blaaaah If I had to pay the full retail price of these medications, I’d be spending about $2880/month. By comparison, the mortgage on my house in Seattle, one of the most expensive housing markets in the US, is $1800. Which is the retail price of Tonmya _alone_. Pharmaceutical pricing is inhumane, and it’s only getting worse, as more and more drugs keep on getting “reformulated” for the sole purpose of protecting them by all-new patents. In most cases these “reformulations” are just different carriers or they add in additional side drugs to supposedly increase the effectiveness.

busybee: fluffy rambles: Medications are expensive beesbuzz.biz/blog/8443-Medications-ar... #Hypercholesterolemia #ClottingDisorder #Fibromyalgia #Medication #Blog #HRT

0 0 0 0
A middle-aged Asian American woman sitting on the steps of a front porch while smiling. Superimposed behind her is a coral parallelogram.

A middle-aged Asian American woman sitting on the steps of a front porch while smiling. Superimposed behind her is a coral parallelogram.

Did you know that 11% of American adults have #HighCholesterol? If you or someone you know has high cholesterol, also known as #hypercholesterolemia, and needs help paying your out-of-pocket prescription costs, we're here to help 💙 Learn more: https://bit.ly/3NqTaFn

#MedSky #FinancialAssistance

0 0 0 0
Preview
Your Cholesterol Numbers: The Good, the Bad, the Triglycerides A Yale Medicine cardiologist explains how to understand your cholesterol screening numbers.

“The primary reason to check #cholesterol in #children is to identify familial #hypercholesterolemia (FH), an inherited defect in the body’s recycling of #LDL cholesterol..impt to identify that #genetic cholesterol problem & treat it early.": buff.ly/rL3v0p5

from @yaleschoolofmed.bsky.social
#genes

4 1 0 0
The image shows 3 graphs depicting change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline. Graph A shows a mean of -59.09%. Graph B displays percent change from baseline. Graph C shows absolute change from baseline in LDL-C.

The image shows 3 graphs depicting change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline. Graph A shows a mean of -59.09%. Graph B displays percent change from baseline. Graph C shows absolute change from baseline in LDL-C.

Monthly subcutaneous SHR-1918, a fully human monoclonal antibody targeting ANGPTL3, was associated with reduced LDL-C in adults with homozygous familial #hypercholesterolemia on stable lipid-lowering therapy.

ja.ma/4bAdazb

1 0 0 0
Preview
Inclisiran offers additional treatment option for adolescents with HeFH The siRNA therapeutic inclisiran significantly reduces LDL cholesterol versus placebo in adolescents undergoing treatment for heterozygous familial hypercholesterolemia, according to the findings of…

#MedNews - The siRNA therapeutic #inclisiran significantly reduces LDL-C vs placebo in adolescents undergoing treatment for heterozygous familial #hypercholesterolemia, according to the findings of the ORION-16 study.

Full story 👉 buff.ly/rEtP04W

#CardioSky

1 0 0 0
Post image

Opportunistic #genomic screening for familial #hypercholesterolemia showed a small, non‑significant drop in LDL‑C, with Bayesian #analysis suggesting a likely benefit. Results hint at #clinical value but need larger trials.

#Genomicscreening

Read More Here: buff.ly/pJiZfj0

2 1 0 0
The image shows three graphs titled 'Figure. Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline'. Graph A: Week 12, Graph B: During study, Graph C: Absolute change.

The image shows three graphs titled 'Figure. Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline'. Graph A: Week 12, Graph B: During study, Graph C: Absolute change.

Monthly subcutaneous SHR-1918, a fully human monoclonal antibody targeting ANGPTL3, was associated with reduced LDL-C in adults with homozygous familial #hypercholesterolemia on stable lipid-lowering therapy. ja.ma/3LpfVbO

1 0 0 0
Post image

💊FDA Approval Update | #Lerochol (#Lerodalcibep-liga)
🔸A third-generation #PCSK9 inhibitor that can reduce #LDL-C in #hypercholesterolemia
🌟Achieved approximately 50% reduction in apolipoprotein B levels + a 24% reduction in lipoprotein(a) in Phase III trial

0 0 0 0
Preview
34-35 PHARMA - Time capsule Time capsule. The ten groundbreaking drugs shaping 2025 and the future

#Vertex #Cysticfibrosis #AstraZeneca #DaiichiSankyo #lungcancer #breastcancer #painmanagement #Alnylam #Sanofi #Haemophilia #Genentech #Roche #MS #MSD #Hypercholesterolemia #Pfizer #InnoventBiologics #EliLilly #Obesity #type2diabetes #GSK #eosinophilicasthma #meningitisvaccine
zurl.co/bzBzK

2 0 0 0
Post image Post image Post image Post image

Dr. Augusto Bleve representing #Italian #Network for #Tumor #Biotherapy ( #NIBIT ) talks on role of #hypercholesterolemia on #anticancer #immunity / #PCSK9 #RORgamma #WIC2025 #SITC2025

1 0 0 1
Video

China NMPA Approves Ebronucimab Injection for Hypercholesterolemia Treatment

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Ebronucimab #PCSK9Inhibitor #CholesterolTreatment #NMPAApproval #ChineseBiologics #Hypercholesterolemia #CardiovascularHealth #KangrongDongfang

0 0 0 0
Preview
Merck’s oral PCSK9 inhibitor finds another Phase III success The pivotal CORALreef Lipids trial assessing enlicitide in hypercholesterolemia patients met all primary and key secondary endpoints.

Merck’s oral PCSK9 inhibitor, enlicitide, met all primary & key secondary endpoints in the Phase 3 CORALreef Lipids trial, showing strong LDL-C lowering & a favorable safety profile. A third successful Phase 3 result for the drug.

#News #Merck #ClinicalTrials #Cardiology #Hypercholesterolemia

0 0 0 0
Preview
Merck’s oral PCSK9 inhibitor finds another Phase III success The pivotal CORALreef Lipids trial assessing enlicitide in hypercholesterolemia patients met all primary and key secondary endpoints.

Merck’s oral PCSK9 inhibitor, enlicitide, met all primary & key secondary endpoints in the Phase 3 CORALreef Lipids trial, showing strong LDL-C lowering & a favorable safety profile. A third successful Phase 3 result for the drug.

#News #Merck #ClinicalTrials #Cardiology #Hypercholesterolemia

0 0 0 0
Preview
An Immune Cell Swallowing “Bad” Cholesterol - Little, Big Science In atherosclerosis, fatty deposits containing cholesterol molecules carried by proteins form on the walls of blood vessels. One of these protein-cholesterol structures is LDL, which is colloquially ca...

🧪🫀In this "Picture in Science" we recreated the cellular process happening in plaques to model #atherosclerosis in a dish.

www.lbscience.org/en/2024/09/1...
#microscopy #macrophages #hypercholesterolemia

16 2 0 0
Post image

How do patient-reported outcomes within the scope of genetic testing for familial #hypercholesterolemia (FH) affect patient management? Relying on standard FH diagnostic criteria without genetic testing may hinder certain treatment coverage by insurers institutionalrepository.aah.org/jpcrr/vol8/i...

1 0 0 0
Post image

Association of cholesterol and glycemic state biomarkers with phenotypic variation and Parkinson's disease progression: The Oxford Discovery cohort - Apr 13, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#hypercholesterolemia #neurology #neurosky #openaccess

0 0 0 0
Preview
One in Four Patients with Severely Elevated Cholesterol Have No Documented Lipid-Lowering Medication Facilitating rapid sharing of new medical knowledge

Data from @heyepic.bsky.social #Cosmos database show patients with documented #hypercholesterolemia are OFTEN not being treated with lipid-lowering meds per ACC/AHA guidelines. The good news is that if you have cardiac-related morbidity, you're much more likely to be treated. #medsky

1 0 0 0
Post image Post image

📢NEW NLA & AGS expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD.

Read the article now: sciencedirect.com/science/arti...

#Cardiosky

3 4 0 1
Post image

Genetic Cholesterol in Children
Throwback to a cover I did in 2023 for The Lancet Diabetes & Endocrinology.
.
#cholesterol #hypercholesterolemia #blood #bloodvessels #heart #heartdisease #genetics #dna #children #health #illustration #editorialillustration #medicalillustration

2 0 0 0

Role of #glucagon in hepatic #lipid #metabolism identified in glucagon-receptor knockout mice. The KO mice on a standard diet showed #hypercholesterolemia and increased #liver fat, yet these changes were masked by fasting-induced #steatosis.

1 0 0 0
Preview
The hypolipidemic effect of MI-883, the combined CAR agonist/ PXR antagonist, in diet-induced hypercholesterolemia model - Nature Communications CAR and PXR receptors are known to regulate metabolism, however, there is no dual human ligand suitable for therapy. Here, the authors show a CAR agonist/PXR antagonist, MI-883, which regulates choles...

#research #metabolism #hypercholesterolemia

The hypolipidemic effect of MI-883, the combined CAR agonist/PXR antagonist, in diet-induced hypercholesterolemia model (Dušek, Nencka) - NatComm: doi.org/10.1038/s414...

@iocbprague.bsky.social @charlesuni.bsky.social @czechacademy.bsky.social

2 1 0 0

Our preclinical data strongly supports the promise of epigenetic editing as a potential ‘one-and-done’ approach for the treatment of #hypercholesterolemia, and more generally as a therapeutic approach to silencing loci without cutting, nicking, or changing the DNA sequence.
8/9

0 0 1 0